1 -2 Activation of platelets on these abnormal surfaces induces platelet recruitment of ambient platelets into forming thrombus by several different pathways, including: 1) adenosine diphosphate (ADP) released from platelet dense granules, 2) thromboxane Aj (TxAj) synthesized by platelets through metabolism of arachidonic acid, and 3) thrombin generated on the platelet surface.
The development of the antiplatelet agent, GT-12, 3 -10 provided the opportunity to investigate its effect on thrombosis in a well-characterized baboon model. 1112 In this model, segments of collagen-coated tubing and Dacron vascular graft are inserted as thrombogenic devices in an exteriorized arteriovenous (A-V) shunt circuit. Covalently bonded collagen-coated tubing and Dacron vascular grafts were selected as thrombogenic surfaces because of their clinical relevance, readily controlled blood flow, segment geometry, and highly reproducible thrombus formation and occlusion. GT-12 is thought to stabilize membrane complexes of the dense tubular system and other storage sites sequestering calcium, thereby blocking the mobilization of additional Ca ++ into the platelet cytosol. 3 -
10

Methods
Normal male baboons (Papio anubis/cynocephalus) were used in these studies. All procedures were approved by the Institutional Animal Care and Use Committee in accordance with federal guidelines (Guide for the Care and Use of Laboratory Animals, 1986). The animals weighed 8 to 12 kg each and had been observed to be disease-free for at least 6 weeks before use. Each animal had a chronic A-V shunt surgically implanted between the femoral artery and vein. This chronic shunt did not detectably activate platelets or coagulation proteins. 12 For surgical procedures, the animals received atropine (0.4 mg/kg intramuscularly) as the preanesthesia and ketamine (10 mg/kg intramuscularly) as the inducing agent. Halothane was used as the anesthetic agent, and butorphenol (0.1 mg/kg twice daily for 2 days) was used for postoperative analgesia.
Segments of Dacron vascular grafts (U.S. Catheter, Billerica, MA; 4.0 mm i.d.) were rendered impervious to blood leakage by an external wrapping of Parafilm (American Can, Greenwich, CT) and were placed inside a 5 cm length of "heat-shrink" Teflon tubing as previously described.
1112 These test segments were interposed between the arms of the permanent A-V shunt, and the blood flow rates were measured continuously with a Doppler ultrasound flowmeter (L&M Electronics, Daly City, CA). In all studies, the initial blood flow rates ranged between 160 and 240 ml/min, with a calculated wall shear rate of 424 to 637 sec" 1 . In these studies, collagencoated silicone rubber tubing was prepared in 2 cm lengths as previously described 13 and was incorporated into the exteriorized A-V shunts distal to the segments of Dacron vascular grafts; the shear rates were calculated to be 844 to 1267 sec" 1 for the collagen segments.
Platelet counts and hematocrit determinations were performed on whole blood collected in 2 mg/ml disodium ethylenediaminetetraacetate (EDTA) with a J.T. Baker (Allentown, PA) Model 810 whole-blood analyzer. Mean whole-blood platelet counts were 405 000±52 000 plateIets//J; hematocrits averaged 34.6%. Bleeding time measurements were performed in duplicate on the shaved volar surface of the forearm by using the standard template method as previously described for studies in baboons. 1415 Autologous baboon blood platelets were labeled with " 1 ln-oxine as previously described. 11 In brief, whole blood (100 ml) was collected directly into plastic bags (TA-3, Fenwal Labs, Deerfield, IL) containing 20 ml of acid-citrate-dextrose anticoagulant (NIH formula A). The blood was centrifuged in the bag at 300 g for 10 minutes. The supernatant platelet-rich plasma (PRP) was transferred to a second bag, and the pH was adjusted to 6.5 by the addition of 0.15 M citric acid (0.1 ml/10 ml PRP). The red blood cell fraction was returned to the donor animal. The platelets were formed into a pellet by centrifugation of the PRP at 13 000 g for 15 minutes. The supernatant platelet-poor plasma (PPP) was completely decanted and discarded. To remove the residual plasma proteins, the bag containing the platelet pellet was carefully washed once by overlaying with 30 ml of Ringers citrate dextrose (RCD, pH 6.5), which was decanted and discarded. The pellet was then gently resuspended in 5.0 ml of RCD and was incubated for 30 minutes with 800 to 1000 fiC\ of "Mn-oxine (Amersham, Arlington Heights, IL). Contaminating red cells were removed by a final slow centrifugation at 200 g for 5 minutes. The labeling efficiencies averaged >90%. All the labeled platelets were re-infused, together with the previously separated red cells, for a total circulating platelet activity of 800 to 950 /xCi.
Images of the Dacron grafts, including proximal and distal silicone rubber segments, were acquired with a Searle PhoGamma V scintillation camera and were stored on and analyzed by a Medical Data Systems A 3 computer (Medtronic, Ann Arbor, Ml) interfaced with the camera. Immediately before imaging the vascular grafts, images were also acquired of 4.0 mm i.d. silicone rubber tubing filled with autologous blood and having the same luminal volume as the graft segment (blood standard). The activities of the standard and 5 cm graft segments were counted in the same region of interest as defined by image analysis software routines. Images were acquired at 5 minute intervals. Deposited 1 "ln-platelet activity calculated by subtracting the blood standard activity from all dynamic study images increased monotonically over the exposure period. The total number of platelets deposited after 1 hour (labeled plus unlabeled cells) was calculated by dividing the deposited platelet activity by the blood standard platelet activity, and multiplying by the volume of the blood standard and the circulating platelet count (platelets/ml)."• 1S The results were expressed as platelets deposited/cm graft.
The concentration of fibrinogen was estimated spectrophotometrically by a modification of Jacobssen's method, 18 in which the optical density of thrombinclottable protein was determined after collection on a glass rod and subsequent solution in 1 % sodium dodecyl sulphate (SDS).
For quantifying the formation of fibrin on the collagen and vascular graft segments, we injected homologous 125 l-fibrinogen (approximately 5 fiC\) intravenously 15 minutes before incorporation of the thrombogenic segments into the A-V shunts. Homologous fibrinogen was purified by /3-alanine precipitation 17 and was labeled with 125 I by using the iodine monochloride method.
1819 This preparation was >95% clottable in vitro. Additionally 95% of the 12S I activity was associated with the clot, thereby documenting that it was functionally equivalent to unlabeled fibrinogen. At the time of segment exposure, blood was collected in EDTA for the determination of both 12S l-fibrinogen activity and fibrinogen concentration, from which the specific activity was calculated. After a 1 hour exposure to flowing blood, the collagen and vascular graft segments were removed from the A-V shunt, were flushed with isotonic buffer, were placed in 10% buffered formalin fixative, and were stored at 4°C. After approximately 30 days, when the '"Inactivity had largely decayed, the 1ia l-activity in each segment was counted and related to the standard and plasma The results were expressed as the total fibrin (mg/cm) contained in the thrombus associated with each segment.
The plasma levels of the platelet-specific a-granule proteins, PF4 and /3TG, and fibrinopeptide A (FPA), a thrombin cleavage product of fibrinogen, were also determined by radioimmunoassay on blood samples collected and processed as described previously. 12 Blood samples for platelet aggregation were collected in 0.1 vol of 3.2% sodium citrate before the start of the infusion, at the end of the infusion, and at the end of the imaging. PRP was prepared by centrifugation at 180 g for 10 minutes, and the concentration was adjusted to 250 000 platelets//xJ with PPP, which was prepared by centrifugation at 13 000 g for 5 minutes. The maximal aggregation response to doses of ADP (Sigma Chemical, St. Louis, MO) and collagen (Hormon Chemie, Munich, FRG) bracketing the full range of reactivity was measured by using a dual-channel aggregometer (Chrono-Log, Havertown, PA). The concentration of agonist required to produce half-maximal aggregation of platelets, ED^,, was calculated for each agonist. man Sciences, Ann Arbor, Ml), and was administered by continuous infusion by using a Harvard pump at the rate of 1 ml/min. Statistical comparisons were made using Student's t test (two-tailed) for paired and unpaired sample groups when the data were normally distributed. The remaining results were compared by using Wilcoxon sign rank test. 21 All values are given as the means±1 SEM.
Results
Ex vivo platelet aggregation to ADP and collagen was significantly reduced after infusion of GT-12 (100 yxmol/kg, 63.3 mg/kg). The ED^ of ADP shifted from 4.7±0.9 ^M to 10.3±2.2 nM (p<0.02), and for collagen from 2.0±0.4 /xg/ml to 8.0±2.4 /xg/ml (p<0.05). Sixty minutes after the infusion of GT-12, the EDso had returned to baseline for both agonists (Table 1) .
The deposition of platelets and fibrin on Dacron graft in six animals treated with GT-12 was reduced in concert by 30% at 60 minutes compared to the matched control values (Table 2) . Moreover, while one graft in the control group occluded at 50 minutes, all the grafts in the animals infused with GT-12 remained patent for the 60 minute observation period with no change in the blood flow. A time course for platelet deposition is displayed in Figure 1 . A significant reduction in the number of deposited platelets was present at each time point. In two animals studied with collagen-coated segments, there was a reduction of fibrin and platelet deposition similar to results using the Dacron graft ( Table 2 ).
The bleeding time was prolonged from a baseline of 4.4±0.4 minutes in the control group to 7.6± 1.0 minutes by GT-12 at the end of the infusion period. There was no Figure 1 . Effect of GT-12 on platelet deposition. Thrombus formation in vivo was measured as the deposition of platelets onto a segment of Dacron vascular graft incorporated into an exteriorized femoral artertovenous shunt during 60 minutes by using gamma camera imaging of autotogous " 1 ln-platelets. A bolus intravenous infusion of GT-12 (100 /unol/kg) before placement of the graft reduced platelet deposition compared with saline-treated controls. change in the fibrinogen concentrations or platelet counts from the control values of 2.86±0.38 mg/ml and 405 000 ±52 000 platelets//J, respectively. The elevation of the platelet-specific ^-granule proteins, PF4 and /3TG, in plasma after the 1 hour exposure to the grafts, was less for the GT-12-treated animals (PF4 values decreased from 24.8+13.9 to 13.2±2.1, p<0.04, Table 3 ). The plasma FPA levels were significantly less in GT-12-treated animals compared to untreated controls (reduced from 10.6±4.3 pmol/l to 5.5±0.9 pmol/l, p<0.05).
Table 3. Effects of GT-12 on Blood Tests of Thrombosis
Determination (n) Untreated
GT-12 (100 /imol/kg) p value Plasma PF4 (ng/ml) Baseline (6) Post-graft (6) Plasma pTG (ng/ml)
Baseline (6) Post-graft ( 
Discussion
The results obtained in these experiments clearty show reduced platelet reactivity and, concomitantJy, decreased thrombus formation on Dacron vascular grafts after infusion of the carbamoylpiperidine congener, GT-12, into baboons compared with the control results (<0.05 in ail cases). The findings for collagen-coated segments appeared to be similar. These in vivo effects were relatively short-lived after bolus infusion. There was a significant prolongation of the bleeding time which, however, normalized within minutes after the bolus infusion of GT-12. ADP-and collagen-induced platelet aggregation also completely normalized at the end of the 60 minute observation period. These findings are concordant with previous in vitro observations of inhibition of platelet aggregation and PF4 release. 2223 The results obtained in the thrombosis model used in this study are quantitative and reproducible and were obtained under physiological conditions of clearance and regulation of activities. Earlier work in this model with aspirin, dipyridamole, suioctidil, and heparin alone or in combination with aspirin or dipyridamole has demonstrated no detectable effect in the platelet deposition or thrombus formation. 11.12.20,24,2s Qn the other hand, ticlopidine, a potent global inhibitor of platelet function, 1226 produces a thrombasthenic-like impairment in platelet hemostatic function with an intermediate effect on platelet deposition, similar to the effects of GT-12. More complete inhibition of platelet deposition on grafts has been reported with murine monoclonal antibodies directed against platelet receptor GPIIb/llla, which blocks the binding of fibrinogen, 15 and the synthetic covalent antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCHaCI). 20 Previous observations indicate that placement of the collagen segment distal to the Dacron vascular graft segment did not affect platelet or fibrin deposition on the collagen surface. 13 For example, in the present study, platelet deposition onto collagen in control studies was 1.81 and 1.33X10 9 plat/cm compared with 1.23±0.21 plat/cm for controls without associated segments of Dacron vascular graft. 13 Similarly, the fibrin deposition onto collagen segments in the present study was compared to previous experience without proximal segments of vascular graft. 13 Thus, the data suggest that proximal positioning of the segment of vascular graft did not affect the thrombogenicity of the collagen segment.
The compound, GT-12, or a,a'-bis[3-(W,rV-diethy1car-bamoyl) piperidino]-p-xylene dihydrobromide, is one of a series of carbamoylpiperidine and nipecotoylpiperazine derivatives that inhibits human blood platelet aggregation. 4 -822 The tertiary amines (structured around the ring nitrogens) in these compounds, identified as aggregation-inhibitory specific functions, 45 are subject to broad variances in protonation contingent upon the pH of their immediate vicinity and upon the specific compounds' pKa values. This very trait enables them in their specifically structured molecules 4 -722 to assume the appropriate hydrophobic character for the penetration of the platelet membrane's lipid bilayer without interfering subsequently with their transformation into corresponding cations. 456 Within this context, the penetrated amines in these surface-active molecules can be envisioned to generate their cationic species in quantities capable of interacting with and reducing the response sensitivity of anionic phospholipids. 27 These conclusions are supported by the findings of Sheetz and Singer 2829 and Ferrel et al., 30 despite the differing views regarding the putative mechanism of action for cationic amphipaths. The compounds are envisioned to stabilize membrane complexes of the dense tubular system and of other storage sites sequestering calcium in the platelets. 731 By enhancing the integrity of these membrane complexes, the compounds restrain Ca ++ release into the platelet's cytosol 6 - 8 and impede activation of phospholipase Aj. 32 Moreover, by reducing the response sensitivity of anionic phospholipids, 27 the compounds render phosphatidylinositol-4,5-biphosphate (PIPJ less susceptible to hydrolysis by phospholipase C and consequently suppress generation of inositoM ,4,5-trisphosphate (IP3), 33 thought to be the principal trigger for the internal discharge of Ca++.34,3B Accordingly, the threshold for initiating or sustaining platelet aggregation becomes elevated.
GT-12 was selected for these studies from among a series of carbamoylpiperidine and nipecotoylpiperazine congeners because of its low acute toxicity in vivo (i.p.) in male ICR mice (LD5o=837 /iM/kg) and its potent inhibition of ADP-induced human platelet aggregation in vitro (laso, 11.4 /u,M). 10 Also, the compound blocks thrombus growth in human whole blood induced by collagen-coated glass under controlled flow (platelets per thrombus reduced by 86.7% at 50 /JM concentrations). 8 Dogs receiving GT-12 intravenously (150 ^mol/kg, 94.9 mg/kg) showed substantial inhibition of ADPinduced platelet aggregation ex vivo. 9 The dose chosen for the present study was based on these preliminary data in dogs in which 50, 100, or 150 ^mol/kg of the compound was injected intravenously over a 3 to 6 minute period 9 ; side effects were noted with the highest dose consisting of salivation, perspiration, and muscle tremors. The infusion of 100 iM/kg in the baboons produced a detectable decrease in blood pressure of about 15 mm Hg in the awake animal lasting about 15 minutes, with no noticeable effect on the heart rate. Higher doses in two baboons were not well tolerated, and lesser doses in two other animals were judged to be ineffective.
The complex mechanisms involved in the formation of thrombus entail several different pathways of activation that interact to a variable extent. We have shown that the infusion of GT-12 in vivo inhibits several pathways of platelet activation and significantly reduces the deposition of platelets and fibrin during the formation of thrombus onto Dacron graft. It is our conclusion that GT-12, an inhibitor of platelet activation, affects platelet-dependent processes and has antithrombotic effects in vivo.
